Jane Wu

2.6k total citations · 2 hit papers
33 papers, 1.3k citations indexed

About

Jane Wu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Infectious Diseases. According to data from OpenAlex, Jane Wu has authored 33 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 5 papers in Infectious Diseases. Recurrent topics in Jane Wu's work include Renal cell carcinoma treatment (5 papers), Emergency and Acute Care Studies (5 papers) and Antifungal resistance and susceptibility (4 papers). Jane Wu is often cited by papers focused on Renal cell carcinoma treatment (5 papers), Emergency and Acute Care Studies (5 papers) and Antifungal resistance and susceptibility (4 papers). Jane Wu collaborates with scholars based in United States, Australia and United Kingdom. Jane Wu's co-authors include Matthew H. Taylor, Daniel E. Stepan, Corina E. Dutcus, Vicky Makker, Robert Shumaker, Chung‐Han Lee, Robert J. Motzer, Drew Rasco, David G. Lange and Mark A. Klausner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

Jane Wu

33 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

2020 359 citations Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology profile →
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

2020 306 citations Matthew H. Taylor, Chung‐Han Lee et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Jane Wu

Since Specialization

Citations

This map shows the geographic impact of Jane Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Wu more than expected).

Fields of papers citing papers by Jane Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Wu. The network helps show where Jane Wu may publish in the future.

Co-authorship network of co-authors of Jane Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Wu. A scholar is included among the top collaborators of Jane Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Wu. Jane Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma 2024 ·Annals of Oncology ·Neeraj Agarwal, James Brugarolas, Pooja Ghatalia, S. George, John B.A.G. Haanen, Howard Gurney, Rahul Ravilla, (unknown), Benoit Beuselinck, И. А. Покатаев, Britt B.M. Suelmann, Mark Tuthill, Daniel A. Vaena, Flora Zagouri, Jane Wu, (unknown), (unknown), (unknown), M.B. Atkins	6
2	1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study 2023 ·Annals of Oncology ·(unknown), James Brugarolas, Pooja Ghatalia, S. George, John B.A.G. Haanen, (unknown), Rahul Ravilla, Astrid A.M. van der Veldt, (unknown), И. А. Покатаев, (unknown), Mark Tuthill, Daniel A. Vaena, Flora Zagouri, Jane Wu, (unknown), Rodolfo F. Perini, (unknown), Michael B. Atkins	4
3	Health care interpreter use in an inpatient rehabilitation setting: examining patterns of use and associated clinical outcomes 2022 ·Disability and Rehabilitation ·Christine T. Shiner, (unknown), Jane Wu, Steven Faux, (unknown)	2
4	Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer breakdown → 2020 ·Journal of Clinical Oncology ·Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James W. Mier, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Mark Messing, Daniel E. Stepan, Corina E. Dutcus, Jane Wu, Emmett V. Schmidt, Robert Orlowski, Perminder S. Sachdev, Robert Shumaker, Antonio Casado	359
5	Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors breakdown → 2020 ·Journal of Clinical Oncology ·Matthew H. Taylor, Chung‐Han Lee, Vicky Makker, Drew Rasco, Corina E. Dutcus, Jane Wu, Daniel E. Stepan, Robert Shumaker, Robert J. Motzer	306
6	Can in-reach multidisciplinary rehabilitation in the acute ward improve outcomes for critical care survivors? A pilot randomized controlled trial 2019 ·Journal of Rehabilitation Medicine ·Jane Wu, (unknown), Christine T. Shiner, Steven Faux, Ian A. Harris, Christopher J. Poulos	8
7	Brain injury rehabilitation after road trauma in new South Wales, Australia – insights from a data linkage study 2018 ·BMC Health Services Research ·Jane Wu, Steven Faux, Christopher J. Poulos, Ian A. Harris	4
8	Record linkage is feasible with non‐identifiable trauma and rehabilitation datasets 2016 ·Australian and New Zealand Journal of Public Health ·Jane Wu, Steven Faux, Ian A. Harris, Christopher J. Poulos, (unknown)	6
9	On assessing the presence of evaluation‐time bias in progression‐free survival in randomized trials 2010 ·Pharmaceutical Statistics ·Richard Kay, Jane Wu, Janet Wittes	4
10	Functional Outcomes of Major Lower Limb Amputation 1994–2006: A Modern Series 2010 ·JPO Journal of Prosthetics and Orthotics ·Jane Wu, (unknown), (unknown)	12
11	LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951) 2009 ·European Journal of Cancer ·Sanjiv S. Agarwala, Ulrich Keilholz, (unknown), Agop Y. Bedikian, Jane Wu, Richard Kay, Cy A. Stein, Loretta M. Itri, Stefan Suciu, Alexander M.M. Eggermont	106
12	Parental Experience of Family Stress During Hematopoietic Stem Cell Transplantation of Pediatric Patients in Germ-free Isolation in Taiwan 2005 ·Cancer Nursing ·Jane Wu, Pei‐Fan Mu, Shiow‐Luan Tsay, Tzeon-Jye Chiou	9
13	Urinary Retention in a General Rehabilitation Unit: Prevalence, Clinical Outcome, and the Role of Screening 2005 ·Archives of Physical Medicine and Rehabilitation ·Jane Wu, Ian Baguley	36
14	Long-Term Follow-Up of HIV-Infected Individuals Who Have Significant Increases in CD4+ Cell Counts during Antiretroviral Therapy 2004 ·Clinical Infectious Diseases ·Susan L. Koletar, Paige L. Williams, Jane Wu, J. Allen McCutchan, Susan E. Cohn, Robert L. Murphy, Howard M. Lederman, Judith S. Currier	26
15	Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients 2001 ·Annals of Allergy Asthma & Immunology ·Jonathan Corren, Harold S. Nelson, Leon S. Greos, George Bensch, Marc F. Goldstein, Jane Wu, Shanshan Wang, Ken B. Newman	40
16	A Pharmacokinetic Study of Intravenous Itraconazole Followed by Oral Administration of Itraconazole Capsules in Patients with Advanced Human Immunodeficiency Virus Infection 1998 ·The Journal of Clinical Pharmacology ·Honghui Zhou, (unknown), Jane Wu, Robert Woestenborghs, Alan E. Hassell, (unknown), Alice Baruch, (unknown), (unknown), L. Joseph Wheat	47
17	Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients 1997 ·Clinical Therapeutics ·Patricia Murray, Susan L. Koletar, (unknown), Jane Wu, Bruce L. Moskovitz	46
18	Effect of a Cola Beverage on the Bioavailability of Itraconazole in the Presence of H₂ Blockers 1997 ·The Journal of Clinical Pharmacology ·David G. Lange, (unknown), Jane Wu, Mark A. Klausner	97
19	A Randomized, Double‐Blind Comparison of Itraconazole Oral Solution and Fluconazole Tablets in the Treatment of Esophageal Candidiasis 1997 ·The Journal of Infectious Diseases ·C. Mel Wilcox, Rabih O. Darouiche, Loren Laine, Bruce L. Moskovitz, (unknown), Jane Wu	70
20	Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate 1995 ·Annals of Surgical Oncology ·E. James Seidmon, Donald L. Trump, Willi Kreis, Stephen W. Hall, Michael R. Kurman, (unknown), Jane Wu, Alton B. Kremer	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact